Is SVB Failure A Sign Of More Uncertainty On The Horizon?

Investors, Advisors Weigh In On Economic Outlook

The Silicon Valley Bank shutdown was a shock but is not likely to harm the biopharma financial ecosystem long term. The bigger near- to mid-term factor is inflation due to its impact on interest rates.

Dominoes falling in the dark
It remains to be seen if the SVB failure is the sign of more banking dominoes to fall • Source: Shutterstock

The failure of Silicon Valley Bank was a shock to biotechnology and high-tech companies that had come to rely on the bank over the past few decades. But while SVB’s failure was unfortunate, it should not have lasting effects on the biopharma industry, investors and investment bankers told Scrip, since other banks are likely to step up to fill the void.

The bigger threat is the uncertainty that lies in macroeconomic factors, such as inflation and whether or not additional bank...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.